Featured Stories

Phenotypic Screening and Target Deconvolution: A Perfect Match

06/21/2016

As a result of Charles River’s continued commitment to emerging drug discovery technologies, a strategic collaboration has been established with caprotec bioanalytics, GmbH, to offer their proprietary protein capture technology for phenotypic screening target deconvolution.

Lessons Learned: The Extended One-Gen Study

06/10/2016

During the finalization of the OECD 443 guideline, Extended One-generation Reproductive Toxicity Study (EOGRTS), scientists at our facilities in Den Bosch, Lyon and Ashland were asked to work on the implementation of this study type and to harmonize the study designs at the sites.

Cost-effective Compound Testing with Single Mouse Trials

06/07/2016

The Single Mouse Trial (SMT) format for in vivo patient-derived xenograft (PDX) studies addresses the need for more cost-effective compound testing in the larger, more diverse tumor populations that can be targeted using our vast portfolio of highly characterized models.

Within Walking Distance – A Cure for Cystic Fibrosis

06/02/2016

On May 14, 2016, Charles River sponsored Great Strides®, a walk supporting the Cystic Fibrosis Foundation. The event brought more than 950 participants to the Cleveland Zoo and raised more than $270,000 to support the search for a cure.

That Was Fast: Health Surveillance Results in Record Time.

05/10/2016

Continuous health surveillance is a critical task in resident animal colony management. Rapid, trusted results provide the information you need to make go/no-go decisions regarding contamination and to avoid the consequences of a biosecurity breach. Charles River has always provided timely, reliable data on every health monitoring sample we process. Our recent laboratory improvements will deliver even greater efficiency and value to our clients.

Curiox Comes to Charles River

05/09/2016

Charles River’s commitment to the 3Rs continues with Curiox miniaturized assays that can be coupled with Luminex® technology. Multiplex panels currently being developed and offered by Charles River include the simultaneous measurement of cytokines, chemokines, hormones and metabolic biomarkers, bone markers, cardiac and muscle injury markers, and renal toxicity biomarkers.

The Future of Rabbit Pyrogen Testing

05/03/2016

During the last year, the move to replace the rabbit pyrogen test whenever possible has increased, especially in Europe. Companies should start to actively discuss this topic internally in order to determine the path forward.

FcγR-Binding Assays with HTRF Readout Now Available

04/28/2016

Charles River now provides FcγR-binding assays with HTRF readout for FcγRI, -II, -III and FcγRn. These assays are used to measure the binding of therapeutic mAbs to Fcγ-receptors and are suitable for assessing biosimilarity.

Displaying results 1-10 (of 102)
 |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|